Bristol Erbitux Ultimatum: Company Wants Control Of FDA Negotiations
Executive Summary
Bristol-Myers Squibb wants responsibility for the regulatory and clinical future of Erbitux under a proposed restructuring of the company's relationship with ImClone
You may also be interested in...
Erbitux Revised Deal Puts Bristol In Charge Of ImClone’s FDA Discussions
Bristol is assuming leadership of ImClone's discussions with FDA regarding resubmission of its colorectal cancer treatment Erbitux according to a revised agreement between the two companies
Erbitux Revised Deal Puts Bristol In Charge Of ImClone’s FDA Discussions
Bristol is assuming leadership of ImClone's discussions with FDA regarding resubmission of its colorectal cancer treatment Erbitux according to a revised agreement between the two companies
Bristol Erbitux Decision Will Follow Feb. 26 FDA Meeting
Bristol-Myers Squibb will decide whether to proceed with the Erbitux collaboration with ImClone after a Feb. 26 meeting with FDA